Clinical Trial Update: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating ipilimumab after stem cell transplantation in relapsed/refractory multiple myeloma was terminated, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-23